NetScientific: $ 1 million investment in holding company, EpiBone


NetScientific plc

(“NetScientific”, the “Group” or the “Company”)

$ 1 million investment in holding company, EpiBone

London, UK – November 26, 2021– NetScientific plc (AIM: NSCI), the international investment and commercialization group for life sciences and sustainable development technologies, announces that it has arranged an additional investment of $ 1million (approximately £ 0.750million) in its Lifesciences holding company, EpiBone Inc. (“Epibone”), a revolutionary regenerative medicine company focused on rebuilding bone and cartilage based in the United States. The investment amount of $ 1 million is part of a Nearly $ 11 million alongside Boston-based investors and notable family offices.

In line with NetScientific’s small cap investment approach, the investment includes $ 734,000 of NetScientific’s balance sheet and $ 266,000 of advised funds from the corporate finance and venture capital subsidiary of EMV Capital Ltd (“EMVC“). This follows the conversion by NetScientific of $ 250,000 of CLA and interest to equity in January 2020 (resulting in 0.82% of the company on a fully diluted basis).The funding will allow EpiBone to achieve a planned scale-up cycle in late 2022 and allow the company to accelerate the development of its pipeline.

The company’s proprietary bioreactor technology is the product of 20 years of basic research and experience in orthopedic tissue engineering, resulting in a three-step process to regenerate human bone. Its main bone product (EB-CMF), a potential treatment for defects in the continuity of the ascending ramus of the mandible, is currently in a phase 1 trial in humans. The first step involves a CT scan to determine the exact size and 3D shape of the bone needed for the defect to be treated, as well as the extraction of adult stem cells. The second step involves creating an accurate and custom scaffolding of the required bone, as well as designing and building a custom bioreactor that will incubate the new bone as it grows. The final step involves infusing the stem cells into the scaffold and growing inside the bioreactor where they are remodeled into a personalized bone graft ready for implantation.

In 2019, EpiBone announced that the United States Food and Drug Administration (FDA) had granted its Investigational New Drug (IND) authorization to conduct a Phase 1/2 clinical trial of its lead bone product, EB- CMF, as a potential treatment for ramus continuity defects in the mandible. The company has received further grants and in November 2020 Professor Robert S. Langer Sc.D., co-founder of Moderna, was appointed to the EpiBone Board of Directors.

The investment is in line with NetScientific’s transatlantic strategy, helping its portfolio companies establish a presence and linkages on both sides of the Atlantic. After the investment, NetScientific seeks to help EpiBone establish a presence in the UK and Europe.

Commenting on the investment,Nina Tandon, CEO of EpiBonesaid, “We welcome NetScientific’s participation in this cycle, providing not only investment but also skills and value-added channels for EpiBone to grow internationally. ”

Dr. Ilian Iliev, CEO of NetScientific commented: We see EpiBone as an emerging leader in regenerative medicine, which is now fully mature. Its platform technology has the potential to transform bone and cartilage space by fabricating implants from patients’ own cells in multiple applications. This is another example of NetScientific’s wise investment approach to taking equity stakes in companies and supporting its transatlantic model, as it accelerates the growth of portfolio companies to generate superior returns on investment. ”

John Clarkson, President of NetScientific commented:“During a planned visit to the Epibone facilities (just before the pandemic hit last year), I was impressed with their technology, development, team and plans. Since then, we have formed a good relationship with the company and have been encouraged by As we continue to implement our stated strategy, this strengthens our “Transatlantic Bridges” program, not only through investment, but also through significantly by now working together to develop and expand Epibone’s business here in the UK and Europe. ”

For more information please contact:

NetScientifique

Via Walbrook PR

Ilian Iliev, CEO

WH Ireland (NOMAD, financial advisor and broker)

Chris Fielding / Darshan Patel

+44 (0) 20 7220 1666

RP Walbrook

Nick Rome / Paul McManus /

Nicolas johnson

07748 325 236, 07980 541 893

or 07884 664 686

About NetScientific

home

NetScientific plc (AIM: NSCI) is a holding company that invests, develops, markets and realizes shareholder value in life sciences / health, sustainability and technology companies, which offer significant growth potential. mainly in the UK and US, as well as globally. .

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, whether in direct subsidiaries, in balance sheet investments or in capital under advice, ranging from private start-ups to equities. listed on the stock exchange.

NetScientific delivers returns to shareholders through a proactive and practical approach to managing its portfolio companies; identify, invest and help create game-changing businesses. The Group targets value inflection points and the release of value through partial or total exits from commercial sales, public listings or sales of shares. The Company has a strong and growing transatlantic and international presence, offering attractive expansion prospects.

NSCI may deploy a small cap investment structure; use the power of the PLC brand and NetScientific’s balance sheet to anchor future investments and achieve a multiplier effect by attracting third-party investments for portfolio companies.

NetScientific is headquartered in London, UK, and was admitted to trading on AIM, a marketplace managed by the London Stock Exchange, in 2013 (website: netscientific.net).

About EMV Capital

emvcapital.com

EMV Capital Ltd is an award-winning London-based investor specializing in B2B companies across healthcare, sustainability and industry. It is a subsidiary of NetScientific PLC listed on AIM. EMVC’s investments in the UK, US and Israel cover a range of technologies including robotics and AI, advanced engineering, power electronics and medical technologies. EMVC’s model is to develop personalized investment strategies for the companies in its portfolio, by combining its network of private investors, institutional venture capitalists and corporate venture capital funds.

About EpiBone

https://www.epibone.com/

EpiBone, Inc. is a privately held regenerative medicine company focused on rebuilding the skeleton. Located at the intersection of biology and engineering, the company harnesses the power of a patient’s own cells to create living solutions that become an integral part of a patient’s body. EpiBone is currently developing a pipeline of bone, cartilage and compound products (bone and cartilage).

EpiBone was co-founded in 2013 by CEO Nina Tandon,Sarindr Bhumiratana and Gordana Vunjak-Novakovic. The company received seed funding in 2014 from the New York City Partnership Fund and Peter Thiel’s Fund, Breakout Labs.


Comments are closed.